Live Earnings Conference Call: Lexeo Therapeutics' Q3 2026 & Study result earnings call is happening now. NASDAQ:LXEO Lexeo Therapeutics Q3 2026 & Study result Earnings Results & Report $2.87 0.00 (0.00%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$3.61 +0.74 (+25.78%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexeo Therapeutics missed analyst earnings expectations in its Q3 2026 & Study result results, released November 16, 2026. The company reported EPS of -$0.43 versus the -$0.33 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026 & Study resultReport DateNovember 16, 2026TimeBefore Market OpensConference Call8:00 AM ET Live Call not available Live EventEarnings Conference CallLexeo Therapeutics Q3 2026 & Study result00:00 / 00:00Live Transcript Follow Audio Lexeo Therapeutics EPS ResultsActual EPS-$0.43Consensus EPS -$0.33Beat/MissMissed by -$0.10One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersLexeo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsLexeo Therapeutics' Q4 2026 earnings is estimated for Monday, December 14, 2026, based on past reporting schedulesConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lexeo Therapeutics Q3 2026 & Study result Earnings FAQ Did Lexeo Therapeutics beat earnings estimates for Q3 2026 & Study result? Lexeo Therapeutics (NASDAQ:LXEO) reported earnings of -$0.43 per share for Q3 2026 & Study result, missing the consensus estimate of -$0.33. The report was announced on Monday, November 16, 2026. When is Lexeo Therapeutics' next earnings date? Lexeo Therapeutics' next earnings date is estimated for Monday, December 14, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexeo Therapeutics on the company's earnings history page. Lexeo Therapeutics Earnings HeadlinesLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial ...20 minutes ago | finance.yahoo.comLexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results1 hour ago | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 16 at 1:00 AM | Weiss Ratings (Ad)Lexeo Therapeutics Announces Date for Third Quarter 2026 Financial Results and Business Update on HEROIC-PKP2 TrialNovember 15 at 9:51 AM | quiverquant.comQLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026November 15 at 9:44 AM | markets.businessinsider.comLexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026November 15 at 7:00 AM | globenewswire.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products. Founded in 2017, Lexeo is based in New York and conducts research and clinical development in the United States. As a clinical-stage company, it focuses on advancing its pipeline rather than marketing approved therapies.View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?Applied Materials Beats and Raises, But Investors Stay Unconvinced3 Power and Grid Stocks That Could Keep Growing Even if AI Spending SlowsYETI Beat on Earnings, But Its Sales Tell a Different Story Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.